Model for Predicting the Effect of Sibutramine Therapy in Obesity

被引:0
|
作者
Danilov, Sergey D. [1 ]
Matveev, Georgiy A. [1 ]
Babenko, Alina Yu. [1 ]
Shlyakhto, Evgeny V. [1 ]
机构
[1] Almazov Natl Med Res Ctr, WCRC Ctr Personalized Med, Lab Prediabet & Metab Disorders, St Petersburg 197341, Russia
来源
JOURNAL OF PERSONALIZED MEDICINE | 2024年 / 14卷 / 08期
关键词
obesity; prediction model; sibutramine; XGBoost classification; Shapley data valuation;
D O I
10.3390/jpm14080811
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The development of models predicting response to weight loss therapy using sibutramine is found in only a few cases. The objective of the work is to develop a data-driven method of personalized recommendation for obesity treatment that would predict the response to sibutramine based on the current set of patient parameters. Methods: The decision system is built on the XGBoost classification algorithm along with recursive feature selection and Shapley data valuation. Using the results of clinical trials, it was trained to estimate the probability of overcoming a weight loss threshold. The model was evaluated by the accuracy metric using the Leave-One-Out cross-validation. Results: The model for predicting response to sibutramine treatment over 3 months has an accuracy of 71%. The model for predicting outcomes at the sixth month visit based on results at 3 months has an accuracy of 80%. Conclusions: Although our developed prediction model may not exhibit high precision compared to certain benchmarks, it significantly outperforms random chance or models relying only on BMI parameters. Our model used the available range of laboratory tests, which makes it possible to use this model for routine clinical use and help doctors decide whether to prescribe sibutramine.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes
    Danielsson, Pernilla
    Janson, Annika
    Norgren, Svante
    Marcus, Claude
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (11): : 4101 - 4106
  • [2] Sibutramine for obesity
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1998, 40 (1022): : 32 - 32
  • [3] Metformine and Sibutramine Therapy in Children and Adolescents with Overwheight and Obesity
    Barbosa, Antonia
    Potter, Marilia
    Alves, Gabriela
    Bornea, Rondi
    Linhares, Rafaela
    De Carvalho, Fernanda
    Cominato, Louise
    Rocha, Ruth
    Passone, Caroline
    Steinmetz, Leandra
    De Menezes, Hamilton Cabral
    Manna, Thais
    Damiani, Durval
    HORMONE RESEARCH IN PAEDIATRICS, 2018, 90 : 61 - 61
  • [4] Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity
    Reisler, G
    Tauber, T
    Afriat, R
    Bortnik, O
    Goldman, M
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2006, 8 (01): : 30 - 32
  • [5] Sibutramine: targeting obesity
    Duntas, Leonidas H.
    Micic, Dragan
    OBESITY AND METABOLISM-MILAN, 2009, 5 (3-4): : 145 - 151
  • [6] Sibutramine and the management of obesity
    Poston, WSC
    Foreyt, JP
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (03) : 633 - 642
  • [7] Sibutramine for obesity in adolescents
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (17) : 2435 - 2438
  • [8] Sibutramine in the management of obesity
    Brunton, S
    JOURNAL OF FAMILY PRACTICE, 2003, 52 (08): : 635 - 635
  • [9] Effect of sibutramine and of cognitive-behavioural weight loss therapy in obesity and subclinical binge eating disorder
    Bauer, C
    Fischer, A
    Keller, U
    DIABETES OBESITY & METABOLISM, 2006, 8 (03): : 289 - 295
  • [10] Behavior therapy and sibutramine for the treatment of adolescent obesity - A randomized controlled trial
    Berkowitz, RI
    Wadden, TA
    Tershakovec, AM
    Cronquist, JL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (14): : 1805 - 1812